Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial.
about
Use of rifaximin in gastrointestinal and liver diseasesEffect of rifaximin on gut microbiota composition in advanced liver disease and its complicationsKinetic mutations in argininosuccinate synthetase deficiency: characterisation and in vitro correction by substrate supplementationManagement of Neurologic Manifestations in Patients with Liver Disease.Covert and Overt Hepatic Encephalopathy: Diagnosis and ManagementHyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.Probiotics and Disease: A Comprehensive Summary-Part 1, Mental and Neurological Health.Probiotics for people with hepatic encephalopathy.Hepatic encephalopathy: what the multidisciplinary team can do.Recent advances in hepatic encephalopathy.Covert Hepatic Encephalopathy: Can My Patient Drive?Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials.The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Pathophysiological Mechanisms and Novel Treatments.The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies.Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled TrialsL-Ornithine L-Aspartate is Effective and Safe for the Treatment of Hepatic Encephalopathy in Cirrhosis
P2860
Q26740201-28A502D3-D588-4F82-98B9-AE345D3397F1Q26775927-D2C359F4-9B2A-47E8-9414-2E20E62D4F2DQ29147513-FBBD8A48-2C50-47E9-A2FA-2CB0456D5E82Q31108752-43F1FD5D-5870-4DA3-AD6D-D29E62654D65Q36199772-A995B2E0-0AAE-407C-8527-6A1335862F61Q37285122-F43CE664-52D4-494B-A4E3-E681291C14C2Q38782270-7E3F0A32-0B20-436E-99B4-B6E07A746E5AQ38946102-F8DD19A5-48B5-4099-88F9-62FEAA544D8EQ39230493-29198A21-417E-40D3-8D5C-818A71E10028Q42353683-A82C2509-ECAA-4C09-81E0-85247C3341A9Q45049715-1B4364EA-256E-47FC-B31E-1601F790E308Q45291275-16C11640-9334-4C31-BF8A-364862092EC0Q47765177-0F8D9A01-8C04-483D-BF2B-EA8D005606B2Q50532497-32CE9E36-E454-452A-8B35-02CFF59EE11FQ57300671-62B2F398-E4E2-499C-9DD9-01F9CBE3E548Q57300691-63252075-D7AF-479F-BD61-EB4A9908E40C
P2860
Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effect of rifaximin, probiotic ...... a randomized controlled trial.
@ast
Effect of rifaximin, probiotic ...... a randomized controlled trial.
@en
Effect of rifaximin, probiotic ...... a randomized controlled trial.
@nl
type
label
Effect of rifaximin, probiotic ...... a randomized controlled trial.
@ast
Effect of rifaximin, probiotic ...... a randomized controlled trial.
@en
Effect of rifaximin, probiotic ...... a randomized controlled trial.
@nl
prefLabel
Effect of rifaximin, probiotic ...... a randomized controlled trial.
@ast
Effect of rifaximin, probiotic ...... a randomized controlled trial.
@en
Effect of rifaximin, probiotic ...... a randomized controlled trial.
@nl
P2093
P2860
P356
P1476
Effect of rifaximin, probiotic ...... a randomized controlled trial.
@en
P2093
Ajeet S Bhadoria
Alok Misra
Kapil Sharma
Manisha Dwivedi
Reshu Tewari
Sanjay Pant
Sriprakash Misra
Sushil Narang
P2860
P304
P356
10.4103/1319-3767.136975
P577
2014-07-01T00:00:00Z